Status:

UNKNOWN

Sedation of Ventilated Traumatic Brain Injury Patients With Midazolam Alone Versus Combination With Dexmedetomidine or Magnesium Sulfate; Monitored by Ultrasonograghic Optic Nerve Sheath Diameter

Lead Sponsor:

Assiut University

Conditions:

TBI (Traumatic Brain Injury)

Eligibility:

All Genders

18-45 years

Phase:

PHASE3

Brief Summary

In TBI, there is a strong correlation between increased ICP and bad outcome. So, appropriate monitoring can be the gold standard in management of TBI. ICP can be measured by invasive and noninvasive m...

Detailed Description

In the previous few years, agreat evidence has established for efficiency of dexmedetomidine (DEX) in management of TBI. Dexmedetomidine is a highly selective alpha-2 receptor agonist, its major sympa...

Eligibility Criteria

Inclusion

  • Middle age patients ( 18- 45 years old).
  • Sever TBI (GCS \< 8 and in need for mechanical ventilation).
  • Stable hemodynamics

Exclusion

  • Age: younger than 18 or older than 45 years old.
  • Mild and moderate TBI (GCS \> 8).
  • Shocked and hypoxic patients.
  • Contraindications to dexmedetomidine as sever hypotension (mean arterial blood pressure \< 60 mmHg), sever bradycardia (heart rate \< 45 beat/min), and AV block in the group that will be sedated by midazolam and dexmedetomidine (group B).
  • Adverse effects of dexmedetomidine in group B and need to stop it as sever hypotension (mean arterial blood pressure \< 60 mmHg) , sever bradycardia (heart rate \< 45 beat/min), and atrial fibrillation.
  • Contraindications to magnesium sulfate as heart block, myocardial damage, hypermagnesemia and renal failure in the group that will be sedated by midazolam and magnesium sulfate (group C).
  • Manifestations of magensium toxicity in group C and need to stop infusion if urine output \< 80 mL in 4 hours, deep tendon reflexes are absent or serum magnesium level \> 3.5 mmol/L .

Key Trial Info

Start Date :

November 1 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2025

Estimated Enrollment :

108 Patients enrolled

Trial Details

Trial ID

NCT05340803

Start Date

November 1 2022

End Date

December 1 2025

Last Update

April 22 2022

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.